- Hyperfine, Inc. (HYPR, Financial) has sold its first commercial units of the next-generation Swoop® Portable MRI system.
- The sales follow FDA clearance and involve two leading hospitals in the northeastern United States.
- The Swoop® system, enhanced by Optive AI™ software, offers improved image quality and is aimed at intensive care and emergency settings.
Hyperfine, Inc. (HYPR), a leader in portable brain imaging technology, has announced the first commercial sales of its next-generation Swoop® Portable MRI systems. These sales come shortly after obtaining FDA clearance, highlighting a strong market response for the advanced MRI technology.
The Swoop® system, powered by proprietary Optive AI™ software, has been acquired by two prestigious hospitals in the northeastern United States. The units are set to enhance diagnostic capabilities in intensive care units and emergency departments, providing unprecedented access to high-quality brain imaging at the point of care.
Maria Sainz, President and CEO of Hyperfine, emphasized this development as a significant step toward the company's mission to transform MRI accessibility. She noted that the rapid progression from development to commercial sales underscores the system’s potential to redefine clinical diagnostics by offering exceptional image quality, improved resolution, and faster acquisition times.
The upgraded Swoop® system is specifically engineered to achieve the highest signal-to-noise ratio available, thus dramatically boosting its clinical application across various healthcare settings. With its user-friendly design, the system is tailored to accommodate a diverse patient demographic, including pediatric and elderly populations, making MRI more accessible to all.
